These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Adverse reaction of LH-RH agonist and its countermeasure]. Oishi K Nihon Rinsho; 2000 Jul; 58 Suppl():202-5. PubMed ID: 11022714 [No Abstract] [Full Text] [Related]
43. Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review. Raj R; Elshimy G; Jacob A; Arya PVA; Unnikrishnan DC; Correa R; Myint ZW J Cancer Res Clin Oncol; 2021 Aug; 147(8):2337-2347. PubMed ID: 34156518 [TBL] [Abstract][Full Text] [Related]
44. Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Guerra Y; Lacuesta E; Marquez F; Raksin PB; Utset M; Fogelfeld L Pituitary; 2010; 13(1):54-9. PubMed ID: 19842040 [TBL] [Abstract][Full Text] [Related]
45. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer. Kobayashi T; Nishizawa K; Mitsumori K Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259 [TBL] [Abstract][Full Text] [Related]
47. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537 [TBL] [Abstract][Full Text] [Related]
48. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
49. Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog. Yu SS; Connolly MK; Berger TG; McCalmont TH J Am Acad Dermatol; 2006 Feb; 54(2 Suppl):S58-9. PubMed ID: 16428002 [No Abstract] [Full Text] [Related]
50. [Giant prostate carcinoma treated effectively with endocrine therapy: case report]. Masue N; Hasegawa Y Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166 [TBL] [Abstract][Full Text] [Related]
51. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. Pathak AS; Pacificar JS; Shapiro CE; Williams SG J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298 [TBL] [Abstract][Full Text] [Related]
52. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study. Raina R; Pahalajani G; Agarwal A; Zippe C Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592 [TBL] [Abstract][Full Text] [Related]
53. Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer. Blumberg JM; Kwon EO; Cheetham TC; Niu F; Shapiro CE; Pacificar J; Loo RK; Williams SG; Chien GW Urology; 2011 Feb; 77(2):412-6. PubMed ID: 21111460 [TBL] [Abstract][Full Text] [Related]
55. [Hypercalcemia: a finding indicative of a prostatic adenocarcinoma]. Llarena Ibarguren R; Acha Pérez M; Zabala Egurrola JA; Pertusa Peña C Actas Urol Esp; 1989; 13(5):409-10. PubMed ID: 2531967 [TBL] [Abstract][Full Text] [Related]
56. Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Fine BA; Munoz AK; Litz CE; Gershenson DM Gynecol Oncol; 2001 Apr; 81(1):120-2. PubMed ID: 11277663 [TBL] [Abstract][Full Text] [Related]
57. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. Iversen P; Karup C; van der Meulen E; Tankó LB; Huhtaniemi I Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):184-90. PubMed ID: 21445092 [TBL] [Abstract][Full Text] [Related]
58. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? Cox MC; Scripture CD; Figg WD Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462 [TBL] [Abstract][Full Text] [Related]
59. Lack of effect of a gonadotropin-releasing hormone agonist in a patient with prostate cancer and a gonadotroph adenoma. Schuval BJ; Kirschenbaum A; Wolfe D; Post KD; Levine AC J Clin Endocrinol Metab; 1996 Feb; 81(2):864. PubMed ID: 8636319 [No Abstract] [Full Text] [Related]
60. Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report. Anda T; Honda M; Ishihara T; Kamei T Neurol Med Chir (Tokyo); 2014; 54(4):327-30. PubMed ID: 24201100 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]